“…These includes sulfonamides (Wadkins et al, 2004), aromatic ethane-1,2 diones (Wadkins et al, 2005;Wadkins et al, 2007;Hyatt et al, 2007b), indole-2,3-diones (Hyatt et al, 2007a), and flurobenzils (Hicks et al, 2007). As CEs are responsible for the metabolism and activation of a host of diverse clinically useful agents, therefore, the development of specific CEs inhibitors may be beneficial in modulating the bioactivity of the agents inactivated by CEs or, conversely, may reduce the toxicity of compounds that are activated by these enzymes (Hyatt et al, 2007a). Consequently, specific CEs inhibitors may have both therapeutic as well as commercial utility .…”